Guardian Pharmacy Services, Inc. (GRDN)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $3.14B
Last updated: Nov 17, 2026 at 11:06 AM ET
Guardian Pharmacy Services, Inc. (GRDN) Stock Forecast
Analysts expect Guardian Pharmacy Services (GRDN) to earn $1.36 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.45B. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 7 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 10.3% and revenue estimates rise 6.9%.
- Fiscal year ending Dec 31, 2026
- $1.36
- EPS consensus, revenue $1.45B
- Fiscal year ending Dec 31, 2027
- $1.50
- EPS consensus, revenue $1.55B
- Next report
- Mar 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.36 | $1.30 to $1.39 | 7 | $1.45B | $1.45B to $1.46B | 7 |
| Dec 31, 2027 | $1.50 | $1.41 to $1.58 | 7 | $1.55B | $1.52B to $1.60B | 7 |
Quarterly Estimates
The EPS consensus falls from $0.41 for the quarter ending Dec 31, 2026 to $0.29 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.41 | $0.36 to $0.47 | 9 | $404.14M | $383.08M to $441.02M | 9 |
| Mar 31, 2027 | $0.29 | $0.26 to $0.30 | 5 | $362.03M | $354.40M to $371.89M | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 12 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 7 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.6% from $1.30.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.36 | $1.30 | $1.30 | $1.30 | $1.30 | +4.7% |
| Fiscal year ending Dec 31, 2027 | $1.50 | $1.43 | $1.43 | $1.43 | $1.43 | +4.6% |
| Quarter ending Mar 31, 2027 | $0.29 | $0.29 | $0.29 | $0.28 | $0.28 | +3.6% |
Frequently Asked Questions About GRDN
What is the GRDN stock forecast?
Consensus analyst estimates put Guardian Pharmacy Services's EPS at $1.36 for the fiscal year ending Dec 31, 2026, on revenue of $1.45B. The consensus rating from 7 analysts is Buy.
How do analysts rate GRDN stock?
Of 7 analysts covering Guardian Pharmacy Services, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GRDN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.36, with estimates from $1.30 to $1.39 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.50, with estimates from $1.41 to $1.58 from 7 analysts.
What revenue do analysts expect from Guardian Pharmacy Services next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.45B, with estimates from $1.45B to $1.46B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.55B, with estimates from $1.52B to $1.60B.
How many analysts cover GRDN?
7 analysts rate Guardian Pharmacy Services stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GRDN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors